Thus, a recent meta-analysis including 45 RCTs and 2,674 individuals with type 2 diabetes mellitus (T2DM) linked ω-3 FA supplementation (ranging from 0.40 to 18.00 g, with duration of supplementation of 2 to 104 weeks) with a significant reduction in plasma levels of tumor necrosis factor-α (TNF-α, P = 0.045) and interleukin-6 (IL-6, P = 0.026) as well as low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein (VLDL), triglycerides (TG), and glycated hemoglobin concentrations (HbA1c)(P ≤ 0.044; all) (27). The gene discussed is IL6; the disease is type 2 diabetes mellitus.